The future of myelofibrosis management will most likely include a combination of agents based on prognostic features and biologic markers of each patient. While myelofibrosis is a rare disease, with an incidence of 1.5 cases per 100,000 people in North America, Europe, and Australia, its impact is not trivial. This symposium will help attendees gain a more complete understanding of myelofibrosis and its connection to other MPNs, as well as the different treatment modalities for this debilitating disease.
Accreditation Statement
Hemedicus, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Hemedicus designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
